What Is the Life Expectancy for Metastatic Bone Cancer?

Median survival after a diagnosis of metastatic bone disease is roughly nine months across all cancer types, but that single number hides enormous variation depending on where the cancer started, how many bones are involved, and what treatments are available. A person with breast cancer that has spread only to a single bone site can live for many years, while someone with lung cancer and widespread skeletal involvement may have only a few months. Understanding what drives those differences is more useful than any single statistic.

Why the Primary Cancer Matters More Than Anything Else

When doctors talk about “metastatic bone cancer,” they almost always mean cancer that originated somewhere else and has spread to the skeleton. The cancer cells in the bone are still lung cells, breast cells, or prostate cells, and they behave accordingly. That distinction explains why survival figures vary so dramatically from one patient to the next.

A five-year prospective study found that the overall median survival for patients with bone metastases was nine months, but the breakdown by primary site tells a very different story: lung cancer patients survived a median of six months, breast cancer patients about 14 months, and prostate cancer patients roughly 24 months.¹ Those gaps reflect the biology of each tumor type. Breast and prostate cancers tend to grow more slowly, respond to hormonal therapies, and generate bone lesions that progress at a pace compatible with years of life. Lung cancer, by contrast, tends to be aggressive, and bone involvement often signals advanced disease with limited systemic treatment options.

Lung cancer with bone metastases carries some of the shortest survival times. One population-based analysis found a median survival of about four months from the time bone metastases were identified at initial diagnosis.² A separate study reported a median of about seven months, with only about a third of patients alive at one year and roughly one in ten at two years.³ Even within lung cancer, survival varies by subtype: small cell lung cancer patients with a single bone metastasis had a median of about 11.5 months compared to around nine months for those with multiple bone lesions.⁴

Kidney cancer with bone metastases falls in a similarly difficult range. Patients with metastatic renal cell carcinoma have a median survival of about eight months, with roughly half dying within the first year and only about one in ten surviving to five years.⁵

For prostate cancer, bone metastases are extremely common but do not always signal imminent death. A large registry-based analysis found that prostate cancer patients with bone metastases who died of their cancer had three-year and five-year survival rates of roughly 48% and 32%, respectively, compared to above 97% for those without bone involvement.⁶ Hormonal therapies, newer androgen-receptor pathway drugs, and bone-targeted treatments have substantially changed the landscape for prostate cancer patients over the past two decades.

Breast Cancer and Bone-Only Metastases

Breast cancer deserves its own discussion because the outlook when it spreads exclusively to bone is strikingly better than for most other cancers. Bone-only metastatic breast cancer carries a median overall survival of more than eight years, with roughly seven out of ten patients alive at five years and about four out of ten at ten years.⁷ Those numbers are measured in years, not months, which is worlds apart from the lung or kidney cancer figures.

Not all bone-only breast cancer behaves the same. A study of 187 breast cancer patients with bone metastases broke them into subgroups: those with a solitary bone lesion had a mean survival of about 14.6 years, while those with multiple bone-only metastases averaged about seven years. Patients whose cancer had also reached other organs (lung, liver, or brain) in addition to bone survived a mean of 6.3 years.⁸ The pattern is clear: the fewer the sites of disease and the more the cancer stays confined to skeleton, the longer the expected survival.

How the Number of Bone Lesions Changes the Picture

Across cancer types, whether you have one bone metastasis or many is one of the strongest predictors of how long you can expect to live. This concept is sometimes described as “oligometastatic” disease, meaning the cancer has spread to only a small number of sites, typically five or fewer.

In breast cancer, the difference is dramatic. Patients with a single bone metastasis had a median survival of about nine years, compared to four years for those with more than one bone lesion.⁹ A separate study confirmed the trend, reporting median survival of about 7.5 years for a single bone metastasis versus roughly 4.8 years for multiple.¹⁰ The location of those metastases also mattered: disease limited to the arms or legs carried a better prognosis than disease in the spine and pelvis combined with the limbs.

The oligometastatic principle applies beyond breast cancer. In small cell lung cancer, patients with a solitary bone metastasis had a two-year survival rate of about 28%, compared to only about 5% for those with multiple bone lesions.⁴ This matters practically because patients with limited skeletal involvement may be candidates for more aggressive local treatments, while widespread bone disease typically shifts the focus toward systemic therapy and symptom management.

Skeletal-Related Events and Their Toll

Bone metastases do not just shorten life expectancy in the abstract. They cause specific complications called skeletal-related events: pathological fractures, spinal cord compression, the need for surgery to stabilize bones, or the need for radiation to control bone pain. These events do not merely reflect advanced disease; they actively worsen the prognosis.

Among prostate cancer patients, those with bone metastases and at least one skeletal-related event had roughly ten times the death rate of men without bone involvement, compared to about 6.6 times for men with bone metastases who avoided those complications.¹¹ A separate analysis of over 3,000 men with metastatic prostate cancer found that experiencing even one skeletal-related event doubled the risk of death. Pathological fractures were the most dangerous, raising the risk nearly threefold. A second event of any type doubled the risk yet again.¹²

Preventing these events has therefore become a major treatment goal. It is not just about comfort, though comfort matters enormously. Keeping bones intact and functional appears to translate directly into longer survival.

Predicting Individual Survival With Scoring Systems

Because survival ranges are so wide, oncologists and orthopedic surgeons use scoring systems to estimate how long a specific patient with bone metastases is likely to live. These estimates guide treatment decisions, particularly around surgery: there is little point in a complex reconstruction if a patient is unlikely to survive long enough to heal, but there is significant benefit if the patient has months or years ahead.

One widely validated scoring system assigns points based on six factors: the type of primary cancer, whether the cancer has also spread to internal organs or the brain, certain laboratory values (like blood counts and markers of organ function), the patient’s overall physical ability, whether they have already received chemotherapy, and whether there are multiple bone metastases.¹³ Scores range from 0 to 10 and divide patients into three risk groups. Those in the low-risk group (scores of three or below, about 13% of patients) had better than 80% survival at one year. The intermediate group (scores of four to six, about 44% of patients) had one-year survival between 30% and 80%. The high-risk group (scores of seven or above, about 43% of patients) had one-year survival at or below 10%.¹³ Validation studies have confirmed that this system correlates well with actual survival and helps clinicians choose appropriate radiation dose schedules and surgical approaches.¹⁴

If your doctor has discussed life expectancy with you, they are likely using a system like this behind the scenes. Asking about your score and which risk group you fall into can give you a more individualized picture than population-wide medians.

Treatments That Protect Bone and May Extend Life

Treatment for bone metastases has two overlapping goals: control symptoms (especially pain and fracture risk) and, where possible, extend survival. Several categories of treatment address these goals.

Bone-Targeted Medications

Two main drug classes are used to prevent skeletal-related events. Bisphosphonates, particularly zoledronic acid, have been the standard for over a decade. Denosumab, a newer injectable medication, works by a different mechanism but targets the same problem: it slows the bone destruction that cancer cells trigger. Head-to-head trials in breast and prostate cancer found that denosumab delayed the time to the first skeletal complication compared to zoledronic acid.¹⁵ A meta-analysis confirmed that denosumab reduced the incidence of skeletal-related events and delayed pain worsening compared to bisphosphonates.¹⁶ Neither drug has shown a clear advantage over the other for overall survival, though, so the choice often comes down to convenience and side-effect profiles.¹⁵

Radium-223 for Prostate Cancer

One treatment that has actually demonstrated a survival benefit specifically for bone metastases is radium-223, a radioactive agent that homes in on areas of active bone turnover. In a landmark trial involving men with castration-resistant prostate cancer and bone metastases, radium-223 extended median overall survival to about 14.9 months compared to 11.3 months with placebo.¹⁷ It also delayed the time to first skeletal-related event by several months and reduced the need for radiation to manage bone pain.¹⁸ However, combining radium-223 with certain hormonal therapies did not improve outcomes and actually increased the fracture rate, so sequencing matters.¹⁹

Radiation and Stereotactic Techniques

Standard radiation therapy has long been used to treat painful bone metastases, and it works well for symptom relief. A newer approach, stereotactic body radiation therapy, delivers a higher and more focused dose. A meta-analysis found that stereotactic radiation was associated with higher overall pain relief rates at three and six months compared to conventional radiation, as well as higher rates of complete pain relief.²⁰ These studies mostly examined patients with a limited number of bone lesions, so the technique is best suited for oligometastatic disease rather than widespread skeletal involvement.

When Surgery Makes Sense

Surgery for bone metastases is almost always palliative, meaning the goal is to restore function and relieve pain rather than cure the cancer. The most common scenario is stabilizing a bone that has fractured or is about to fracture due to tumor weakening. After surgical fixation of pathological femur fractures, one study found a median postoperative survival of about 8.4 months, with lower blood protein levels and more aggressive primary tumor types predicting shorter survival.²¹

An important shift in surgical thinking is that some teams now recommend operating based on the patient’s current functional status rather than their estimated life expectancy. The reasoning is that maintaining the ability to walk and perform daily activities matters regardless of whether the patient has two months or two years left.²² This is a meaningful departure from older approaches that sometimes denied surgery to patients with short predicted survival, leaving them bedridden for their remaining time.

Survival Is Getting Longer

One piece of genuinely encouraging news is that survival after treatment of metastatic bone disease has been improving over time, and the trend is consistent across most cancer types.²³ Better systemic therapies (immunotherapies, targeted agents, improved hormonal treatments), better surgical techniques, better radiation delivery, and the availability of bone-protective drugs like denosumab and zoledronic acid have all contributed. The figures cited throughout this article reflect the current evidence, but someone diagnosed today may do better than historical data suggest, particularly if their cancer type has seen recent treatment advances.

Molecular Profiling and the Future of Prognosis

Researchers are working on gene-expression-based tools that go beyond clinical scoring systems. For prostate cancer, a 14-gene signature has shown promise in predicting which patients with bone metastases will have shorter or longer survival, and it may eventually help guide drug selection, including identifying patients likely to resist certain hormonal treatments.²⁴ These tools are still in the validation phase and are not yet part of routine clinical practice, but they point toward a future where survival estimates are tailored not just to the tumor type and extent of disease but to the molecular characteristics of an individual patient’s cancer. For now, the best prognostic picture comes from combining the factors already discussed: what the primary cancer is, how many bones are involved, whether visceral organs are also affected, and how well the patient is functioning day to day.